With arteriovenous fistula (AVF) becoming increasingly prevalent worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising need for safer and more effective treatment solutions. According to DelveInsight, the AVF pipeline includes 3+ pharmaceutical and biotech companies actively developing 3+ therapeutic candidates targeting this condition. These therapies are in various stages of clinical and preclinical development, reflecting substantial innovation and a strong commitment to addressing a major public health challenge.
DelveInsight’s “Arteriovenous Fistula Pipeline Insight 2025” report offers a comprehensive evaluation of the ongoing R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, serving as a vital resource for stakeholders—including researchers, investors, and healthcare decision-makers—looking to understand the evolving AVF therapeutics market and the innovations shaping its future.
Explore the Cutting-Edge Landscape of Arteriovenous fistula Drug Development
Key Takeaways from the Arteriovenous fistula Pipeline Report
-
DelveInsight’s Arteriovenous Fistula pipeline report highlights an active landscape with 3+ companies developing 3+ pipeline therapies for the treatment of AV fistula.
-
In April 2025, Sonavex received FDA 510(k) clearance for its EchoMap™ device, which employs 3D ultrasound technology to deliver real-time, quantitative blood flow data, aiming to improve AV fistula monitoring and management at the point of care.
-
In December 2024, the FDA granted premarket approval to Merit Medical’s Wrapsody™ cell-impermeable endoprosthesis. This device is designed for hemodialysis patients to address stenosis or occlusion within the dialysis access outflow circuit, including peripheral veins of AV fistulas and the venous anastomosis of synthetic AV grafts.
-
Key companies such as Enceladus Pharmaceuticals, Kintara Therapeutics, Symic Bio, and others are actively developing new therapies to enhance the AV fistula treatment landscape. Promising pipeline candidates include liposome-encapsulated prednisolone and other novel therapies currently in various stages of development.
Arteriovenous fistula Overview:
An arteriovenous (AV) fistula is an abnormal link between an artery and a vein, allowing blood to flow directly from the artery into the vein, bypassing the capillary network. Small AV fistulas in locations such as the arms, legs, lungs, kidneys, or brain are generally not dangerous, but larger untreated fistulas can cause serious health complications. While AV fistulas can develop anywhere in the body, they are more frequently observed in the head, neck, spine, and liver. They may be congenital or arise due to trauma, genetic conditions, or complications from medical procedures like cardiac catheterization. In individuals with advanced kidney disease, AV fistulas are often surgically created to facilitate dialysis. Diagnosis typically involves a detailed medical history, physical examination, and imaging studies such as duplex ultrasound, CT angiography, or MR angiography. Small fistulas may resolve on their own and only require monitoring, whereas larger ones often necessitate intervention through methods like endovascular embolization, ultrasound-guided compression, microsurgery, or stereotactic radiosurgery.
Download the Arteriovenous fistula sample report to know in detail about the Arteriovenous fistula treatment market
Arteriovenous fistula Pipeline Analysis
The Arteriovenous fistula pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Arteriovenous fistula Market.
-
Categorizes Arteriovenous fistula therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Arteriovenous fistula drugs under development based on:
-
Stage of development
-
Arteriovenous fistula Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Arteriovenous fistula Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Arteriovenous fistula Licensing agreements
-
Funding and investment activities supporting future Arteriovenous fistula market advancement.
-
Unlock key insights into emerging Arteriovenous fistula therapies and market strategies here: https://www.delveinsight.com/report-store/arteriovenous-fistula-av-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Arteriovenous fistula Emerging Drugs
-
Liposome encapsulated prednisolone: Enceladus Pharmaceuticals
Liposomal prednisolone, an arachidonic acid inhibitor, is under investigation in a Phase II clinical trial for treating arteriovenous (AV) fistulas. Preclinical studies in mice have demonstrated that this liposome-encapsulated formulation can decrease vascular inflammation and encourage outward remodeling of the vein.
Arteriovenous fistula Pipeline Therapeutic Assessment
Arteriovenous fistula Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Arteriovenous fistula By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Arteriovenous fistula Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Arteriovenous fistula Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Arteriovenous fistula therapies and key Arteriovenous fistula companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. Arteriovenous fistula Current Treatment Patterns
4. Arteriovenous fistula - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Arteriovenous fistula Late-Stage Products (Phase-III)
7. Arteriovenous fistula Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Arteriovenous fistula Discontinued Products
13. Arteriovenous fistula Product Profiles
14. Arteriovenous fistula Key Companies
15. Arteriovenous fistula Key Products
16. Dormant and Discontinued Products
17. Arteriovenous fistula Unmet Needs
18. Arteriovenous fistula Future Perspectives
19. Arteriovenous fistula Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Arteriovenous fistula pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
